Coronavirus Update: UK Trials Six Candidates
As Merck & Co Joins Vaccine Quest
The UK Government’s Therapeutics Taskforce has identified a number of drug candidates that could be used to treat COVID-19 and the first candidate is ready to enter clinical trials.
You may also be interested in...
Emerging Company Profile: UK biotech Pneumagen expects to enter clinical studies in 2021 with a potential first-in-class glycan-targeted protein for preventing respiratory tract infections.
AstraZeneca, during a strong first-quarter update, underscored its determination to test existing portfolio assets for use in fighting the COVID-19 pandemic.
Overall, the pharma lowered its 2020 revenue guidance by $2.5bn at the midpoint, but also says it will save about $400m on SG&A expenses. Pandemic impacts expected mainly in Q2, normal resumption in Q4.